Clinical Trial Update: A Randomized, Double-blind, Multicenter Phase III Study of XNW5004 Tablets in Patients With Relapsed or Refractory Peripheral T-cell Lymphoma [Phase 3]

View source ↗

Summary

A Phase III randomized, double-blind multicenter study evaluating XNW5004 tablets in patients with relapsed or refractory peripheral T-cell lymphoma, currently …

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Peripheral T-cell Lymphoma

Drugs mentioned

• XNW5004

Snippet

Sponsor: Evopoint Biosciences Inc. | Conditions: Relapsed/Refractory Peripheral T Cell Lymphoma | Phase 3 | Status: RECRUITING